Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adapted mRNA COVID-19 vaccine
- Development stage
- Approved
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
Adapted mRNA COVID-19 vaccines are second-generation messenger RNA vaccines designed to provide enhanced protection against SARS-CoV-2 variants, particularly the Omicron lineage. These vaccines, such as the bivalent formulations of Comirnaty (BioNTech/Pfizer) and Spikevax (Moderna), utilize lipid nanoparticle technology to deliver mRNA sequences encoding the spike protein of specific variants (e.g., BA.1 or BA.4/5) alongside or instead of the original ancestral strain. Upon administration, host cells translate the mRNA into viral proteins, triggering both humoral (antibody) and cellular (T-cell) immune responses. In the context of a prospective observational study conducted by the University Hospital Bonn (Universitätsklinikum Bonn), these vaccines were evaluated in high-risk healthcare employees to assess the durability of adaptive immunity and the influence of physical fitness on infection outcomes.
- Brand names
- ComirnatySpikevax
- Other names
- adapted mRNA COVID-19 vaccineOmicron-adapted mRNA vaccinebivalent mRNA COVID-19 vaccinevariant-adapted mRNA vaccine
02
Targets
RibosomeInnate immune RNA pattern recognition receptorHuman adaptive immune receptors recognizing SARS-CoV-2 spikeACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on adapted mRNA COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adapted mRNA COVID-19 vaccine.